AZD-6738
-
Technical Data
Description
AZD-6738 is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, AZD-6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.
Related products
ABT-263 (Navitoclax)
from $50.00
MEK-162 (ARRY-162)
from $60.00
E-7090
from $280.00
E-7080 (Lenvatinib Mesylate)
from $80.00